Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 4:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 210 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: RSV Infection Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (RSV LID cp ΔM2-2) in RSV-Seronegative Infants and Children 6 to 24 Months of Age

NCT02948127
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV LID cp ΔM2-2 Vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
3
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 16, 2018 · Synced Jul 23, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

NCT01852266
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV cps2 Vaccine, Placebo Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 24 Months
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2013
U.S. locations
2
States / cities
Baltimore, Maryland • Laurel, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Jul 23, 2026, 4:15 AM EDT
Not listed No phase listed Observational

Continuous Exhaled Breath Condensate pH in Mechanically Ventilated Patients

NCT00429637
View directory record Official record
Conditions
Respiratory Distress Syndrome, Adult, Respiratory Syncytial Virus Infections, Pneumonia, Acute Lung Injury
Interventions
Not listed
Lead sponsor
University of Virginia
Other
Eligibility
1 Hour and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2009
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Aug 6, 2008 · Synced Jul 23, 2026, 4:15 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Rilematovir in Infants and Children and Subsequently in Neonates Hospitalized With Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus (RSV)

NCT04583280
View directory record Official record
Conditions
Respiratory Tract Infections
Interventions
Rilematovir, Rilematovir X mg/kg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
1 Day to 5 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Orlando, Florida • Jackson, Mississippi • The Bronx, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 23, 2026, 4:15 AM EDT
Completed No phase listed Observational

An Epidemiological Study to Evaluate the RSV-Associated Lower Respiratory Track in Infections in Infants

NCT00369759
View directory record Official record
Conditions
Respiratory Infections, Bronchiolitis, Pneumonia, Apnea
Interventions
Emergency Dept. Subjects with LRI or Apnea
Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
1 Day to 12 Months
Enrollment
2,048 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
38
States / cities
Phoenix, Arizona • Sylmar, California • Denver, Colorado + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2009 · Synced Jul 23, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

NCT04886596
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Placebo, RSVPreF3 OA vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
60 Years and older
Enrollment
26,675 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
60
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 54 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Jul 23, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of RSV Monoclonal Antibody RSM01 in Healthy Adults

NCT05118386
View directory record Official record
Conditions
RSV Infection
Interventions
RSM01, Placebo
Drug · Other
Lead sponsor
Gates Medical Research Institute
Other
Eligibility
18 Years to 49 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2024 · Synced Jul 23, 2026, 4:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study of ALVR106 in Patients With Respiratory Viral Infections After Hematopoietic Cell and Solid Organ Transplant

NCT04933968
View directory record Official record
Conditions
Respiratory Tract Viral Infections, Human Metapneumovirus (hMPV) Infection, Parainfluenza (PIV) Infection, Respiratory Syncytial Viral (RSV) Infection, Influenza Infection
Interventions
ALVR106, Placebo
Biological
Lead sponsor
AlloVir
Industry
Eligibility
17 Years to 75 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
21
States / cities
Scottsdale, Arizona • Duarte, California • Gainesville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Jul 23, 2026, 4:15 AM EDT
Completed No phase listed Observational

Association Between Cytokines and Severity of Respiratory Syncytial Virus (RSV)-Induced Illness in the Elderly

NCT00609635
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
Not listed
Lead sponsor
West Penn Allegheny Health System
Other
Eligibility
65 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 5, 2009 · Synced Jul 23, 2026, 4:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study on a Live-attenuated Respiratory Syncytial Virus Vaccine for Assessment of Safety, Transmissibility, and Genetic Stability of the Vaccine Virus Among Close Contacts in Infants and Toddlers 6 to < 24 Months of Age in Puerto Rico (USA)

NCT05687279
View directory record Official record
Conditions
Respiratory Syncytial Virus Infection
Interventions
RSVt Vaccine, Control Group
Biological · Other
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 23 Months
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Norfolk, Nebraska • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 23, 2026, 4:15 AM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

A Study of Safety, Reactogenicity and Immune Response of the Repeat Vaccination Against RSV When Given to Female Participants of 18-49 Years of Age During Their Subsequent Uncomplicated Pregnancy

NCT05229068
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSV MAT
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 49 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Missoula, Montana • Norfolk, Nebraska
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Jul 23, 2026, 4:15 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults

NCT07628049
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections+Metapneumovirus
Interventions
RSV/hMPV_V low dose vaccine, RSV/hMPV_V medium dose vaccine, RSV/hMPV_V high dose vaccine, RSV/hMPV_W low dose vaccine, RSV/hMPV_W medium dose vaccine, RSV/hMPV_W high dose vaccine, RSV/hMPV_X low dose vaccine, RSV/hMPV_X medium dose vaccine, RSV/hMPV_X high dose vaccine, hMPV_Y low dose vaccine, hMPV_Y medium dose vaccine, hMPV_Y high dose vaccine, hMPV_Z low dose vaccine, hMPV_Z medium dose vaccine, hMPV_Z high dose vaccine, Control vaccine, Placebo
Biological · Combination Product
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,808 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
2
States / cities
Lenexa, Kansas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 4:15 AM EDT
Completed Phase 4 Interventional Results available

Intermittent Use of Aerosolized Ribavirin for Treatment of RSV

NCT00500578
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Ribavirin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
5 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 31, 2012 · Synced Jul 23, 2026, 4:15 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended Lower Respiratory Tract Infection Due to Respiratory Syncytial Virus in Healthy Late Preterm and Term Infants (MELODY)

NCT03979313
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MEDI8897, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 1 Year
Enrollment
3,012 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
66
States / cities
Birmingham, Alabama • Fort Defiance, Arizona • Fayetteville, Arkansas + 59 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2024 · Synced Jul 23, 2026, 4:15 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II

NCT02911935
View directory record Official record
Conditions
Respiratory Syncytial Virus, Bronchiolitis
Interventions
Oral azithromycin, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
1 Month to 18 Months
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 6, 2022 · Synced Jul 23, 2026, 4:15 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

MVA-BN-RSV Vaccine Trial

NCT05238025
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
MVA-BN-RSV vaccine, Tris Buffered Saline (TBS)
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
60 Years and older
Enrollment
20,419 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
105
States / cities
Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 86 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2024 · Synced Jul 23, 2026, 4:15 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, and Pharmacokinetics of Clesrovimab (MK-1654) in Infants (MK-1654-002)

NCT03524118
View directory record Official record
Conditions
Respiratory Tract Infection, Respiratory Syncytial Virus
Interventions
Clesrovimab, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Weeks to 8 Months
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
17
States / cities
Aurora, Colorado • Homestead, Florida • Miami, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jul 23, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Presatovir in Hematopoietic Cell Transplant Recipients With Respiratory Syncytial Virus Infection of the Upper Respiratory Tract

NCT02254408
View directory record Official record
Conditions
Respiratory Syncytial Virus
Interventions
Presatovir, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
27
States / cities
Phoenix, Arizona • Duarte, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2018 · Synced Jul 23, 2026, 4:15 AM EDT
Recruiting Phase 3 Interventional

Azithromycin Treatment for Respiratory Syncytial Virus-induced Respiratory Failure in Children

NCT05026749
View directory record Official record
Conditions
Respiratory Syncytial Virus Infections
Interventions
AZM Group, Control Group
Drug · Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
3 Days to 2 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
15
States / cities
Birmingham, Alabama • San Francisco, California • New Haven, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Jul 23, 2026, 4:15 AM EDT
Completed No phase listed Observational

Evaluation of Performance of the LumiraDx Influenza A/B + RSV Test at POC Testing Sites

NCT04288921
View directory record Official record
Conditions
Influenza, Human, Respiratory Syncytial Virus Infections
Interventions
Swab
Diagnostic Test
Lead sponsor
LumiraDx UK Limited
Industry
Eligibility
Not listed
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
20
States / cities
Birmingham, Alabama • Encinitas, California • Madera, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 23, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics Study of Multiple Ascending Doses of BTA-C585 in Healthy Volunteers

NCT02668367
View directory record Official record
Conditions
Pharmacokinetics, Healthy Volunteers
Interventions
BTA-C585 oral capsules, BTA-C585 matching placebo
Drug
Lead sponsor
Biota Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2018 · Synced Jul 23, 2026, 4:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Infection Watch Study

NCT04623047
View directory record Official record
Conditions
COVID-19 Respiratory Infection, Respiratory Syncytial Virus Infections, Rhinoviral Infections, Influenza Viral Infections
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
10,034 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2024 · Synced Jul 23, 2026, 4:15 AM EDT
Completed Phase 2 Interventional Results available

Evaluate the Safety and Tolerability, for Nirsevimab in Immunocompromised Children

NCT04484935
View directory record Official record
Conditions
RSV Infection
Interventions
Nirsevimab
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
0 Years to 2 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
7
States / cities
Los Angeles, California • Tampa, Florida • Syracuse, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2023 · Synced Jul 23, 2026, 4:15 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Challenge Infection of Healthy Adult Volunteers With RSV A2

NCT03388645
View directory record Official record
Conditions
Upper Respiratory Tract Infections
Interventions
10^6.3 PFU of RSV A2, 10^7 PFU of RSV A2
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 2, 2020 · Synced Jul 23, 2026, 4:15 AM EDT